Top

Journal of Autism and Developmental Disorders

Gepubliceerd in:

01-05-2013 | Original Paper

A Retrospective Study of Amitriptyline in Youth with Autism Spectrum Disorders

Auteurs: Irfan Bhatti, Andrew Thome, Patricia Oxler Smith, Galen Cook-Wiens, Hung Wen Yeh, Gary R. Gaffney, Jessica A. Hellings

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 5/2013

Abstract

We performed a retrospective chart review of 50 youths with Autism Spectrum Disorder (ASD), prescribed amitriptyline (AMI) for hyperactivity and impulsivity. Data was systematically extracted from 50 outpatient clinic charts, including AMI treatment duration, dose, trough levels and adverse events. Mean age was 9.4 years (4.6–17.9); 40 were males and 10 females. 30 % had failed atomoxetine and 40 % had failed ≥3 ADHD medications. Mean dose was 1.3 ± 0.6 mg/kg/day, mean trough level 114.1 ± 50.5 ng/ml, mean duration 3.4 years. Clinical Global Impressions Scale-Improvement (CGI-I) was ≤2 in 60 % of patients at the final visit, and in 82 % of patients for at least 50 % of follow-ups. Cautious use of low dose AMI shows promise for treatment-resistant youth with ASD accompanied by hyperactivity, impulsivity, aggression and self injury.

vorige artikel Using the Prevent-Teach-Reinforce Model with Families of Young Children with ASD

volgende artikel Development of T-STAT for Early Autism Screening

Akuffo, E., MacSweeney, D. A., & Gajwani, A. K. (1986). Multiple pathology in a mentally handicapped individual. BJP, 149, 377–378.CrossRef

Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 89, 485–491.PubMed

Anderson, G. M., Freedman, D. X., Cohen, D. J., Volkmar, F. R., Hoder, E. L., McPhedran, P., et al. (1987). Whole blood serotonin in autistic and normal subjects. Journal of Child Psychology and Psychiatry, 28, 885–900.PubMedCrossRef

Arnold, L. (2006). Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 1196–2005.PubMedCrossRef

American Medical Association. (1991). Clomipramine in the treatment of patients with obsessive-compulsive disorder. The clomipramine collaborative study group. Archives of General Psychiatry, 48, 730–738.

Biederman, J., & Jellinek, M. S. (1984). Psychopharmacology in children. New England Journal of Medicine, 310, 968–972.PubMedCrossRef

Campbell, M. (1988). Fenfluramine treatment of autism. Journal of Child Psychology and Psychiatry, 29, 1–10.PubMedCrossRef

Campbell, M., Anderson, L. T., Small, A. M., Locascio, J. J., Lynch, N. S., & Choroco, M. C. (1990). Naltrexone in autistic children: A double-blind and placebo-controlled study. Psychopharmacology Bulletin, 26, 130–135.PubMed

Chadwick, W., Mitchell, N., Caroll, J., Zhou, Y., Park, S. S., Wang, L., et al. (2011). Amitriptyline-mediated cognitive enhancement in aged 3 × tg Alzheimer’s disease mice is associated with neurogenesis and neurotrophic activity. PLoS ONE, 6, e21660.PubMedCrossRef

Cohen, I. L., Campbell, M., Posner, D., Small, A. M., Triebel, D., & Anderson, L. T. (1980). Behavioral effects of haloperidol in young autistic children: An objective analysis using a within-subjects reversal design. Journal of the American Academy of Child Psychiatry, 19, 665–677.PubMedCrossRef

Collier, R. (2009). Drug development cost estimates hard to swallow. CMAJ, 180, 279–280.PubMed

Correll, C. U., Manu, P., Olshanskiy, V., Napolitano, B., Kane, J. M., & Malhotra, A. K. (2009). Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. Journal of American Medical Association, 302, 1765–1773.CrossRef

Davidson, J. (1990). Treatment of posttraumatic stress disorder with amitriptyline and placebo. Archives of General Psychiatry, 47, 259–266.PubMedCrossRef

Dhillon, S., Hellings, J. A., & Butler, M. G. (2011). Genetics and mitochondrial abnormalities in autism spectrum disorders: A review. Current Genomics, 12, 322–332.PubMedCrossRef

Frye, R. E., & Rossignol, D. A. (2011). Mitochondrial dysfunction can connect the diverse medical symptoms associated with autism spectrum disorders. Pediatric Research, 69, 41R–47R.PubMedCrossRef

Ganz, M. L. (2007). The lifetime distribution of the incremental societal costs of autism. Archives of Pediatrics and Adolescent Medicine, 161, 343–349.PubMedCrossRef

Geller, E., Ritvo, E. R., Freeman, B. J., & Yuwiler, A. (1982). Preliminary observations on the effect of fenfluramine on blood serotonin and symptoms in three autistic boys. New England Journal of Medicine, 307, 165–169.PubMedCrossRef

Gordon, C. T., State, R. C., Nelson, J. E., Hamburger, S. D., & Rapoport, J. L. (1993). A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Archives of General Psychiatry, 50, 441–447.PubMedCrossRef

Guy, W. (1976). ECDEU Assessment Manual for Psychopharmacology (MNIH Publication NO. 76–338). Washington, DC: US DHEW NIMH.

Hellings, J. A., Zarcone, J. R., Crandall, K., Wallace, D., & Schroeder, S. R. (2001). Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. Journal of Child and Adolescent Psychopharmacology, 11, 229–238.PubMedCrossRef

Hellings, J. A., Zarcone, J. R., Valdovinos, M. G., Reese, R. M., Gaughan, E., & Schroeder, S. R. (2005). Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 15, 885–892.PubMedCrossRef

Hellings, J. A., Zarcone, J. R., Reese, R. M., Valdovinos, M. G., Marquis, J. G., Fleming, K. K., et al. (2006a). A crossover study of risperidone in children, adolescents and adults with mental retardation. Journal of Autism and Developmental Disorders, 36, 401–411.PubMedCrossRef

Hellings, J.A., Tanjim, S., Saranga, V., Thome, A. (2006a). Comorbidity and combination treatments with dextroamphetamine in youth with autism spectrum disorders (ASD) and attention deficit hyperactivity disorder (ADHD). [Poster] 50th Annual Meeting (NCDEU) Boca Raton, FL.

Hellings, J. A., Cardona, A., & Schroeder, S. R. (2010). Long-term safety and adverse events of risperidone in children, adolescents and adults with pervasive developmental disorders. Journal of Mental Health Research in Intellectual Disabilities, 3, 132–144.CrossRef

Hellings, J. A., Boehm, D., Yeh, H., & Schroeder, S. R. (2011). Long-term clinical aripiprazole efficacy and weight changes in youth with developmental disabilities including autism spectrum disorders. Journal of Mental Health Research in Intellectual Disabilities, 4, 1–14.CrossRef

Hellweg, R., Ziegenhorn, A., Heuser, I., & Deuschle, M. (2008). Serum concentrations of nerve growth factor and brain-derived neurotrophic factor in depressed patients before and after antidepressant treatment. Pharmacopsychiatry, 41, 66–71.PubMedCrossRef

Horvath, K., & Perman, J. A. (2002). Autistic disorder and gastrointestinal disease. Current Opinion in Pediatrics, 14, 583–587.PubMedCrossRef

Jackson, J. (2010). Tricyclic antidepressants and headaches: systematic review and meta-analysis. BMJ, 341, c5222.PubMedCrossRef

Kim, Y. S., Leventhal, B. L., Koh, Y., Fombonne, E., Laska, E., Lim, E., et al. (2011). Prevalence of autism spectrum disorder in a population sample. American Journal of Psychiatry,. doi:10.1176/appi.ajp.2011.10101532,2011.

King, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahill, L., Bregman, J. D., et al. (2009). STAART psychopharmacology network: Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: Citalopram ineffective in children with autism. Archives of General Psychiatry, 66, 583–590.PubMedCrossRef

Kuperman, S., Beeghly, J. H. L., Burns, T. L., & Tsai, L. Y. (1985). Serotonin relationships of autistic probands and their first-degree relatives. Journal of the American Academy of Child Psychiatry, 24, 186–190.PubMedCrossRef

Lecavalier, L., Leone, S., & Wiltz, J. (2006). The impact of behaviour problems on caregiver stress in young people with autism spectrum disorders. Journal of Intellectual Disability Research, 50, 172–183.PubMedCrossRef

Lord, C., Rutter, M., & Le Couteur, A. (1994). Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. Journal of Autism and Developmental Disorders, 24, 659–685.PubMedCrossRef

Marcus, R. N., Owen, R., Kamen, L., Manos, G., McQuade, R. D., Carson, W. H., et al. (2009). A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 48, 1110–1119.PubMedCrossRef

Max, M. (1987). Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology, 37, 589–596.PubMedCrossRef

Owen, R., Sikich, L., Marcus, R. N., Corey-Lisle, P., Manos, G., McQuade, R. D., et al. (2009). Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics, 124, 1533–1540.PubMedCrossRef

Perry, R., Campbell, M., Adams, P., Lynch, N., Spencer, E. K., Curren, E. L., et al. (1989). Long-term efficacy of haloperidol in autistic children: Continuous versus discontinuous drug administration. Journal of the American Academy of Child and Adolescent Psychiatry, 28, 87–92.PubMedCrossRef

Posey, D. J., Wiegand, R. E., Wilkerson, J., Maynard, M., Stigler, K. A., & McDougle, C. J. (2006). Open-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 16, 599–610.PubMedCrossRef

Prince, J. B., Wilens, T. E., Biederman, J., Spencer, T. J., Millstein, R., Polisner, D. A., et al. (2000). A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 10, 193–204.PubMedCrossRef

Research Units in Pediatric Psychopharmacology (RUPP) Autism Network. (2002). Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine, 347, 314–321.CrossRef

Research Units in Pediatric Psychopharmacology (RUPP) Autism Network. (2005). Randomized, controlled crossover trial of methylphenidate in pervasive development disorder with hyperactivity. Archives of General Psychiatry, 62, 1266–1327.CrossRef

Richelson, E., & Nelson, A. (1984). Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. JPET, 230, 94–102.

Rush, A. (2007). STAR*D: What have we learned? American Journal of Psychiatry, 02(164), 201.CrossRef

Sandman, C. A., Barron, J. L., & Colman, H. (1990). An orally administered opiate blocker, naltrexone, attenuates self-injurious behavior. American Journal of Mental Retardation, 95, 93–102.PubMed

Stahl, S. M. (2008). Classical antidepressants, serotonin selective reuptake inhibitors and noradrenergic reuptake inhibitors. In Stahl’s essential psychopharmacology: Neuroscientific basis and practical application. Cambridge: Cambridge University Press.

Tamminga, C. A. (2011). When is polypharmacy an advantage? American Journal of Psychiatry, 168, 663.PubMedCrossRef

Wilens, T. E., Biederman, J., Prince, J., Spencer, T. J., Faraone, S. V., Warburton, R., et al. (1996). Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. American Journal of Psychiatry, 153, 1147–1153.PubMed

CDC Autism Report. (2010). www.cdc.gov/mmwr/preview/mmwrhtml/ss5810a1.htm.

Zarcone, J. R., Lindauer, S. E., Morse, P. S., Crosland, K. A., Valdovinos, M. G., McKerchar, T. L., et al. (2004). Effects of risperidone on destructive behavior of persons with developmental disabilities: III. Functional analysis. American Journal of Mental Retardation, 109, 310–321.PubMedCrossRef

Titel: A Retrospective Study of Amitriptyline in Youth with Autism Spectrum Disorders
Auteurs: Irfan Bhatti
Andrew Thome
Patricia Oxler Smith
Galen Cook-Wiens
Hung Wen Yeh
Gary R. Gaffney
Jessica A. Hellings
Publicatiedatum: 01-05-2013
Uitgeverij: Springer US
Gepubliceerd in: Journal of Autism and Developmental Disorders / Uitgave 5/2013
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI: https://doi.org/10.1007/s10803-012-1647-0

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen

Andere artikelen Uitgave 5/2013

Autism Training in Pediatric Residency: Evaluation of a Case-Based Curriculum

Using the Prevent-Teach-Reinforce Model with Families of Young Children with ASD

The Specificity of Inhibitory Impairments in Autism and Their Relation to ADHD-Type Symptoms

Excess Mortality and Causes of Death in Autism Spectrum Disorders: A Follow up of the 1980s Utah/UCLA Autism Epidemiologic Study

The French Version of the Autism-Spectrum Quotient in Adolescents: A Cross-Cultural Validation Study

A Comparison of Social Cognitive Profiles in children with Autism Spectrum Disorders and Attention-Deficit/Hyperactivity Disorder: A Matter of Quantitative but not Qualitative Difference?